The pro-angiogenic activity of urotensin-II on human vascular endothelial cells involves ERK1/2 and PI3K signaling pathways

被引:18
作者
Guidolin, Diego [1 ,2 ]
Albertin, Giovanna [1 ,2 ]
Oselladore, Barbara [1 ,2 ]
Sorato, Elisa [1 ,2 ]
Rebuffat, Piera [1 ,2 ]
Mascarin, Alessandra [1 ,2 ]
Ribatti, Domenico [3 ,4 ]
机构
[1] Univ Padua, Sch Med, Dept Human Anat, Sect Anat, I-35121 Padua, Italy
[2] Univ Padua, Sch Med, Dept Physiol, Sect Anat, I-35121 Padua, Italy
[3] Univ Bari, Sch Med, Dept Human Anat, Bari, Italy
[4] Univ Bari, Sch Med, Dept Histol, Bari, Italy
关键词
Angiogenesis; Human endothelial cells; Urotensin-II; Signaling pathways; RECEPTOR GPR14; GROWTH-FACTOR; HUMAN TISSUES; IN-VITRO; CAROTID ATHEROSCLEROSIS; INCREASED EXPRESSION; RAT; PROLIFERATION; VASOCONSTRICTOR; ADRENOMEDULLIN;
D O I
10.1016/j.regpep.2010.02.009
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Human vascular endothelial cells express the urotensin-II (U-II) receptor and exhibit a strong in vitro angiogenic response to the peptide. Thus, in the present study an in vitro model, based on human umbilical vein endothelial cells (HUVEC) cultured on Matrigel, was used to characterize more in detail the signaling pathways that control the pro-angiogenic action of U-II. The activation of the U-II receptor (UT) was associated with an increase of intracellular calcium concentration. Both calcium rise and pro-angiogenic effect of the peptide can be blocked by U73122, a selective inhibitor of phospholipase-C, indicating that the signal transduction from UT mainly involves the phospholipase-C/IP3 pathway. As far as the downstream signaling pathways are concerned, western blot analyses and experiments with specific inhibitors indicated that the U-II-induced self-organization of the cells into capillary-like structures was PKC dependent and involved the activation of the ERK1/2, but not p38-MAPK, transduction pathway. Interestingly, the pharmacological inhibition of PI3K (obtained with LY294002), hindered the capacity of U-II to induce a proangiogenic effect on HUVEC, suggesting that PI3K-dependent pathways also play a role in regulating the process. (C) 2010 Elsevier B.V. All rights reserved.
引用
收藏
页码:26 / 32
页数:7
相关论文
共 48 条
[1]   Pro-angiogenic activity of Urotensin-II on different human vascular endothelial cell populations [J].
Albertin, Giovanna ;
Guidolin, Diego ;
Sorato, Elisa ;
Spinazzi, Raffaella ;
Mascarin, Alessandra ;
Oselladore, Barbara ;
Montopoli, Monica ;
Antonello, Michele ;
Ribatti, Domenico .
REGULATORY PEPTIDES, 2009, 157 (1-3) :64-71
[2]   Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14 [J].
Ames, RS ;
Sarau, HM ;
Chambers, JK ;
Willette, RN ;
Alyar, NV ;
Romanic, AM ;
Louden, CS ;
Foley, JJ ;
Sauermelch, CF ;
Coatney, RW ;
Ao, ZH ;
Disa, J ;
Holmes, SD ;
Stadel, JM ;
Martin, JD ;
Liu, WS ;
Glover, GI ;
Wilson, S ;
McNulty, DE ;
Ellis, CE ;
Elshourbagy, NA ;
Shabon, U ;
Trill, JJ ;
Hay, DWP ;
Ohlstein, EH ;
Bergsma, DJ ;
Douglas, SA .
NATURE, 1999, 401 (6750) :282-286
[3]   Increased expression of urotensin II and its cognate receptor GPR14 in atherosclerotic lesions of the human aorta [J].
Bousette, N ;
Patel, L ;
Douglas, SA ;
Ohlstein, EH ;
Giaid, A .
ATHEROSCLEROSIS, 2004, 176 (01) :117-123
[4]   State-dependent calcium mobilization by urotensin-II in cultured human endothelial cells [J].
Brailoiu, Eugen ;
Jiang, Xiaohua ;
Brailoiu, G. Cristina ;
Yang, Jun ;
Chang, Jaw Kang ;
Wang, Hong ;
Dun, Nae J. .
PEPTIDES, 2008, 29 (05) :721-726
[5]   Biochemical and functional characterization of high-affinity urotensin II receptors in rat cortical astrocytes [J].
Castel, Helene ;
Diallo, Mickael ;
Chatenet, David ;
Leprince, Jerome ;
Desrues, Laurence ;
Schouft, Marie-Therese ;
Fontaine, Marc ;
Dubessy, Christophe ;
Lihrmann, Isabelle ;
Scalbert, Elisabeth ;
Malagon, Maria ;
Vaudry, Hubert ;
Tonon, Marie-Christine ;
Gandolfo, Pierrick .
JOURNAL OF NEUROCHEMISTRY, 2006, 99 (02) :582-595
[6]   Plasma concentration of urotensin II is raised in hypertension [J].
Cheung, BMY ;
Leung, R ;
Man, YB ;
Wong, LYF .
JOURNAL OF HYPERTENSION, 2004, 22 (07) :1341-1344
[7]   Pharmacology of the urotensin-II receptor antagonist palosuran (ACT-058362; 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea sulfate salt):: First demonstration of a pathophysiological role of the urotensin system [J].
Clozel, M ;
Binkert, C ;
Birker-Robaczewska, M ;
Boukhadra, C ;
Ding, SS ;
Fischli, W ;
Hess, P ;
Mathys, B ;
Morrison, K ;
Müller, C ;
Müller, C ;
Nayler, O ;
Qiu, CB ;
Rey, M ;
Scherz, MW ;
Velker, J ;
Weller, T ;
Xi, JF ;
Ziltener, P .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2004, 311 (01) :204-212
[8]   In vitro culture of rat neuromicrovascular endothelial cells on polymeric scaffolds [J].
Conconi, MT ;
Lora, S ;
Baiguera, S ;
Boscolo, E ;
Folin, M ;
Scienza, R ;
Rebuffat, P ;
Parnigotto, PP ;
Nussdorfer, GG .
JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A, 2004, 71A (04) :669-674
[9]   Cloning of the cDNA encoding the urotensin II precursor in frog and human reveals intense expression of the urotensin II gene in motoneurons of the spinal cord [J].
Coulouarn, Y ;
Lihrmann, I ;
Jegou, S ;
Anouar, Y ;
Tostivint, H ;
Beauvillain, JC ;
Conlon, JM ;
Bern, HA ;
Vaudry, H .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (26) :15803-15808
[10]   Human urotensin-II as a novel cardiovascular target: 'heart' of the matter or simply a fishy 'tail'? [J].
Douglas, SA .
CURRENT OPINION IN PHARMACOLOGY, 2003, 3 (02) :159-167